Eyam Health Graduates from Creative Destruction Lab with Large-Animal Proof of Concept and Expanding Pharma Pipeline
VANCOUVER, BC, CANADA, June 11, 2026 /EINPresswire.com/ — Eyam Health today announced its graduation from the Creative Destruction Lab (CDL) Vancouver Biomedical stream, exiting the program at a decisive inflection point. Over nine months, Eyam validated its proprietary Gemini platform in two large-animal species, including durable single-administration expression approaching six months, grew its roster of … Read more